(Total Views: 198)
Posted On: 11/14/2022 1:10:52 PM
Post# of 39

$ASMB News Article - Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334 https://marketwirenews.com/news-releases/asse...44982.html


My Twitter: WhyteStocks